Approval of the First Biosimilar in the US Opens the Doors of a Lucrative Market
The much awaited biosimilars have finally entered the US pharmaceutical market with the FDA approval of Sandoz's Zarxio, a G-CSF. The move is expected to make US a significant region for biosimilar activity.
View full press release